# Inluriyo

NDC: 0002-1717
Generic name: imlunestrant
Labeler / Manufacturer: Eli Lilly and Company
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, FILM COATED
Routes: ORAL
Marketing started: 20250925

FDA application: NDA218881

## Active ingredients

- IMLUNESTRANT: 200 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0002-1717"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0002-1717
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5bc172e4-e8a2-441a-be52-279a7f890196